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Summary
Female middle age is characterized by a decline in skeletal muscle
mass and performance, predisposing women to sarcopenia,
functional limitations, and metabolic dysfunction as they age.
Menopausal loss of ovarian function leading to low circulating
level of 17b-estradiol has been suggested as a contributing factor
to aging-related muscle deterioration. However, the underlying
molecular mechanisms remain largely unknown and thus far
androgens have been considered as a major anabolic hormone
for skeletal muscle. We utilized muscle samples from 24 pre- and
postmenopausal women to establish proteome-wide profiles,
associated with the difference in age (30–34 years old vs. 54–
62 years old), menopausal status (premenopausal vs. post-
menopausal), and use of hormone replacement therapy (HRT;
user vs. nonuser). None of the premenopausal women used
hormonal medication while the postmenopausal women were
monozygotic (MZ) cotwin pairs of whom the other sister was
current HRT user or the other had never used HRT. Label-free
proteomic analyses resulted in the quantification of 797 muscle
proteins of which 145 proteins were for the first time associated
with female aging using proteomics. Furthermore, we identified
17b-estradiol as a potential upstream regulator of the observed
differences in muscle energy pathways. These findings pinpoint
the underlying molecular mechanisms of the metabolic dysfunc-
tion accruing upon menopause, thus having implications for
understanding the complex functional interactions between
female reproductive hormones and health.
Key words: estrogenic regulation; female muscle; functional
annotation; hormone replacement therapy; label-free protein
quantitation; nano-LC-HD-MSE.
Introduction
Skeletal muscle aging is characterized by progressive decline in muscle
mass and function predisposing to sarcopenia, functional limitation, and
metabolic dysfunction (Cruz-Jentoft et al., 2010). Muscle aging is a
multifactorial process affected by intrinsic factors such as endocrine
changeover, neuronal remodeling, muscle regeneration deficiency and
deterioration of cell death regulation, and extrinsic factors such as diet,
physical activity, sedentariness, or other lifestyle choices (Demontis et al.,
2013).
Up until loss of ovarian function at menopause, 17b-estradiol (E2) is
the most prominent biologically active circulating female sex hormone.
Among fertile premenopausal women, the circulating serum concen-
tration of E2 fluctuates from few tens of pmols L
1 to over
1000 pmol L1 depending on a phase of the menstrual cycle (Laven
& Fauser, 2006). Menopausal transition is characterized by irregular
menstrual cycle leading eventually to amenorrhea, concomitantly with
a shift in hormonal balance from higher E2 and lower follicle-
stimulating hormone (FSH) to constantly low E2 and high FSH levels
(Harlow et al., 2012; Baber et al., 2016). Although sex differences in
skeletal muscle metabolism and the role of ovarian hormones and
benefits of postmenopausal hormone replacement therapy (HRT) in
combating aging-related decrements of muscle properties have gained
a significant interest in last decades (e.g., Greising et al., 2009; Velders
& Diel, 2013; Sipila¨ et al., 2015; Gheller et al., 2016), current
knowledge base is overwhelmingly contributed by male studies with
fewer input coming from studies concentrating on female-specific
aspects of aging.
The circulating female hormone pool is not the only hormonal pool
affecting muscle properties. We have recently shown that intramuscular
E2 concentration is associated with muscle strength and power,
independently from the E2 concentration in the circulation (Po¨lla¨nen
et al., 2015). The origin of intramuscular hormones and their exact
molecular functions are currently unknown. Muscle tissue may directly
respond to circulating E2 as well as uptake dehydroepiandrosterone
(DHEA), testosterone, or other precursor hormones, to be converted to
biologically active E2, which then contributes to the intracellular
signaling. It is well documented that muscle cells express estrogen and
androgen receptors enabling receptor-dependent signaling and direct
interactions with other pathways such as IGF-1/Akt signaling (Olivieri
et al., 2014). To gain a more comprehensive view on the responses of
skeletal muscle to hormonal aging, multiple -omics approaches, includ-
ing transcriptomics, proteomics, and metabolomics are desired.
Recently, a French research consortium identified 67 putative
biomarkers of muscle aging by comparing muscle samples from groups
of 56- and 78-year-old postmenopausal women (Gueugneau et al.,
2014; Theron et al., 2014). Candidate proteins for muscle aging were
classified into eight functional groups, including myofilaments and
cytoskeleton, energy metabolism, detoxification, cytoprotection, signal
transduction, proteostasis, proteolysis, and serum proteins. However, in
these studies the role of hormone status on muscle aging was not
investigated. To complement the previous investigations on aging female
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muscle proteome, we focused on possible differences evoked by
menopause-associated hormonal aging in adult premenopausal and
middle-aged postmenopausal women. In the current study, we inves-
tigated the age- and hormone status-associated differences in female
muscle proteome in relation to differences in muscle performance. We
used skeletal muscle samples of premenopausal (30- to 34-year-old)
women in comparison with postmenopausal (54- to 62-year-old) women
who were either never exposed to or current HRT users. Moreover, we
utilized a genetically controlled cotwin model to investigate the
relationship between HRT and muscle proteome among postmenopausal
women with, on average of 7-year discordance, in the history of HRT
use. Finally, potential differences due to different types of HRT, namely
E2- or tibolone-based product, were investigated. This approach enabled
determination of differences in female muscle proteome that are
associated with hormonal aging, that is, differences in age and E2 and
pinpointing E2 as a major regulator of female muscle energy and cell
death pathways.
Results and discussion
Clinically and phenotypically characterized female muscle samples were
lysed and subjected to data-independent nano-LC-HD-MSE analysis,
followed by protein identification and relative abundance quantitation
using the Progenesis QI for Proteomics platform. Subsequently,
functional characterization using Ingenuity Pathway Analysis (IPA)
software was performed. We determined the proteomic differences
and the affected molecular pathways due to differences in age and
hormonal status as well as predicted upstream regulators of the affected
pathways. Due to differences in the functional mechanism of estrogen-
based (E2-HRT) and tibolone-based (Tib-HRT) HRT, the proteomics
analysis was performed separately for these subgroups.
Clinical characteristics of study participants
Study participants included six healthy 30- to 34-year-old premenopausal
women and 18 women from nine pairs of 54- to 62-year-old
postmenopausal monozygotic (MZ) cotwin sisters discordant for current
HRT use (Ronkainen et al., 2009; Po¨lla¨nen et al., 2011). The clinical and
gynecological characteristics are summarized in Table 1. Among the HRT
using twin sisters, three used HRT medication which contained only
estradiol and three a medication which included estradiol and progesto-
gen forming the E2-HRT group, while another three used tibolone-
containing HRT (Tib-HRT group), known to possess estrogenic, pro-
gestogenic, and androgenic functions (Dubey et al., 2004; Hanifi-
Moghaddam et al., 2005). As estradiol-only HRT and estradiol plus
progestogen HRT are based on the utilization of estradiol as a main
functional hormone, and there were no phenotypic differences between
the users (data not shown), these two groups were combined to increase
Table 1 Clinical data of the study participants
Premenopausal
n = 6
Postmenopausal
nonusers
n = 9
Postmenopausal
HRT users
n = 9
Age (years) 31.8  1.8 57.3  2.2 57.3  2.2
Health and lifestyle variables
Number of chronic diseases or conditions
Allergy (n) 4 2 1
Musculoskeletal problems (n) 4 4 3
Migraine (n) 3 1 0
Cancer history (n) 0 1 0
Hypertension with medication (n) 0 4 5
Current smokers (n) 2 1 1
Physical activity
Sedentary (n) 0 1 1
Moderately active (n) 3 3 3
Active (n) 3 5 4
Gynecological data
Age at first menstruation (years) 13.3  2.0 12.9  1.4 12.6  1.0
Age at last menstruation (years) Still menstruating 48.7  4.2 50.7  2.0
Number of participants with regular menstrual cycle (n) 6 No cycle No cycle
Mean length of the cycle (days) 28.3
Number of participants been pregnant (n) 4 8 7
Number of pregnancies per participant (n) 0–3 0–3 0–3
Number of participants having used hormonal contraceptive during past
10 years; but not within last 5 years (n)
3 1 1
Number of participants with ovariectomy and/or hysterectomy (n) 0 1 3
Number of participants reporting menopausal symptoms 0 9 7
Use of HRT Never Never Currently
Duration of HRT use (years) 7.3  3.3
Number of E2-HRT users (n) 3
Number of E2+progestogen-HRT users (n) 3
Number of Tib-HRT users 3
Data are presented either as mean  standard deviation or as total number of participants. HRT = hormone replacement therapy, E2 = 17b-estradiol, Tib = tibolone.
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the statistical power of the proteomic analysis. All participants were in
good self-reported health, although some of them reported minor
medical conditions such as allergies, musculoskeletal problems,
migraine, or had hypertension with medication (Table 1). Furthermore,
one postmenopausal woman had a history with malignant melanoma,
for which she had undergone treatment for 15 years before the study
onset.
The phenotype characteristics of the study participants are presented
in Table 2. There were no significant differences in body composition
between pre- and postmenopausal women, but according to handgrip
strength measurements, premenopausal women were stronger than
non-HRT postmenopausal women. Premenopausal women were also
more powerful than postmenopausal women regardless of the HRT
status, and the HRT users had greater muscle power than their nonusing
cotwins (Table 2). The expected menopause- and HRT status-related
differences were seen in systemic hormones status, namely in the
circulating concentrations of E2, testosterone, luteinizing hormone (LH),
and FSH (Table 2). As we have previously demonstrated (Po¨lla¨nen et al.,
2015), there were no differences in intramuscular steroid hormone levels
except for higher dihydrotestosterone (DHT) levels in postmenopausal
HRT users and nonusers compared to premenopausal women.
To investigate the potential cotwin differences in clinical character-
istics between E2-HRT and Tib-HRT groups, the mean intrapair differ-
ences within both groups were calculated (Table 3). Among the E2-HRT
group, intrapair differences existed for muscle power, systemic E2, sex
hormone-binding globulin (SHBG), and for intramuscular DHT while
among Tib-HRT group a significant difference between the sisters was
observed in specific muscle force. E2- and Tib-HRT groups differed from
each other in specific force and systemic E2, testosterone, and SHBG
levels. These results further confirm that E2- and Tib-HRT have different
mechanisms of function, which subsequently leads to differences in the
phenotype.
General characterization of female muscle proteome
Using nano-LC-HD-MSE, we identified in total 1583 proteins of which
797 were quantified (Table S1, Supporting information) and subjected to
further analysis by applying the following scheme: (i) Postmenopausal
nonhormone users (non-HRT; n = 9) were compared to premenopausal
women (PRE; n = 6), in order to identify hormonal aging-associated
differences at low E2 background; (ii) postmenopausal E2-HRT users
(n = 6) were compared to PRE (n = 6), in order to identify hormonal
aging-associated differences at E2-supplemented background; and (iii) to
identify HRT-use-associated differences at genetically controlled, same
age background, two separate comparisons were made: (iii-a) Post-
menopausal E2-HRT women (n = 6) were compared to their nonusing
cotwins (n = 6); and (iii-b) postmenopausal Tib-HRT users (n = 3) were
compared to their nonusing cotwins (n = 3).
Using this strategy and applying stringent filtering (│fold change (FC)
> 1.5│, P < 0.05, ≥ 2 unique peptides observed by nano-LC-HD-MSE)
to identify differentially expressed proteins (DEPs, Table S2, Supporting
information), we identified hormonal aging-associated differences in the
Table 2 Phenotype characteristics of the study participants. Statistically significant P-values are marked in bold
Premenop. Women
(n = 6)
Postmenop. nonusers
(n = 9)
Postmenop. HRT users
(n = 9)
P-values
PRE vs. nonusers PRE vs. HRT users HRT- vs. nonusers
Body composition
BMI (kg m2) 23.1  2.2 26.9  4.6 25.4  2.4 0.082 0.079 0.261
Waist circumference (cm) 80.8  10.1 90.1  10.1 85.5  5.0 0.106 0.252 0.176
Hip circumference (cm) 97.0  5.3 102.6  7.9 99.8  5.3 0.156 0.338 0.074
Body fat mass (kg) 15.7  5.1 23.9  8.9 19.8  4.8 0.064 0.135 0.121
LBM (kg) 43.3  3.3 44.9  4.0 45.7  2.6 0.437 0.146 0.527
Muscle performance
Handgrip (N) 333.6  45.7 258.9  36.1 289.1  57.0 0.004 0.134 0.218
Power (cm) 26.6  5.7 12.6  3.8 15.5  2.8 <0.001 <0.001 0.011
Specific force (N cm2) 10.1  1.8 9.8  1.7 9.4  1.5 0.732 0.424 0.470
Systemic hormones†
E2 (pmol L
1) 461.7  308.2 26.0  8.5 151.0  233.9 <0.001 0.008 0.018
Testosterone (nmol L1) 1.1  0.4 0.8  0.3 0.7  0.2 0.224 0.050 0.374
DHT (pmol L1) 468.3  319.8 201.1  110.8 268.9  91.2 0.026 0.181 0.141
DHEAS (lmol L1) 4.4  1.6 3.2  1.5 3.5  1.7 0.066 0.088 0.374
LH (IU L1) 9.6  5.3 32.7  15.6 28.6  6.0 0.001 0.001 0.214
FSH (IU L1) 6.2  1.7 82.9  20.3 54.9  26.1 <0.001 <0.001 0.015
SHBG (nmol L1) 54.2  18.4 54.1  23.8 54.3  29.3 0.689 0.864 0.767
Intramuscular hormones†
E2 1.3  0.1 1.3  0.3 1.2  0.2 0.776 0.607 0.058
Testosterone 11.8  1.8 12.3  2.5 11.0  1.6 0.689 0.529 0.086
DHT 0.5  0.1 0.9  0.2 0.8  0.1 <0.001 <0.001 0.011
DHEA 70.1  11.1 70.7  14.7 61.9  11.8 0.776 0.224 0.110
Data are presented as mean  standard deviation. HRT = hormone replacement therapy, BMI = body mass index, LBM = lean body mass, E2 = 17b-estradiol,
DHT = dihydrotestosterone, DHEA(S) = dehydroepiandrosterone (sulfate), LH = luteinizing hormone, FSH = follicle-stimulating hormone, SHBG = sex hormone-binding
globulin.
†Due to nonlinear distribution of hormone variables, Mann–Whitney U-test for independent samples was used to test significance of group means in PRE vs. nonuser and PRE
vs. HRT user comparisons and Wilcoxon signed rank test for related samples to test significance of group means in HRT vs. nonuser comparison.
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relative abundance of 114 proteins at low E2 background (non-HRT vs.
PRE) and 151 proteins at E2-supplemented background (E2-HRT vs. PRE).
Furthermore, E2-HRT users differed from their non-HRT cotwins in the
relative abundance of 53 proteins, while Tib-HRT users differed from
their non-HRT cotwins in the relative abundance of 95 proteins.
The identified DEPs were compared in order to identify unique and
shared molecular processes related to age- and HRT-associated differ-
ences (Fig. 1). When postmenopausal non-HRT women or HRT using
women were compared to the premenopausal women, 93 shared
proteins were identified in both comparisons indicating that the use of
HRT does not affect the age-related differences in the abundance of
these proteins (Fig. 1A, Table S3, Supporting information). Moreover, 21
proteins were unique to non-HRT vs. PRE comparison, and 58 to HRT
users vs. PRE comparison. Furthermore, we identified 12 HRT-associated
proteins regardless the HRT type, 41 proteins specific to E2-HRT, and 83
proteins specific to Tib-HRT (Fig. 1B, Table S3, Supporting information).
As a part of our validation scheme, we compared our results and the
findings of previous muscle proteomics studies on postmenopausal
aging between 56 and 78 years of age (Gueugneau et al., 2014; Theron
et al., 2014). Among the age-associated DEPs (114 proteins at low E2
background and 151 proteins at E2-supplemented background), 27
proteins have been previously described (Fig. 1C, Table S3, Supporting
information). In addition to previously known age-associated DEPs, we
identified 145 novel proteins to be associated with pre- to post-
menopausal hormonal aging occurring between in 30–34 and 54–
62 years of age. Seventy-nine of them were present in both aging
conditions with or without HRT. This indicates that although we were
able to identify several novel muscle proteins with abundance influenced
by aging, 54% of them were not sensitive to the use of HRT and, thus,
potentially are not affected by the circulating level of E2. However, the
use of same younger control group in both comparisons may decrease
variation between comparisons and, thus, increase the similarity of the
findings.
Functional muscle proteomics
The lists of DEPs were subsequently functionally annotated with IPA. In
total, 39 canonical pathways were found to be significantly affected
(Benjamini–Hochberg adjusted P value, B-H P < 0.05) in one or more
comparisons (Table S4, Supporting information). Closer characterization
of the identified pathways and their contributing proteins demonstrated
grouping in three major functional clusters associated with mitochon-
drial functions, cytoplasmic energy metabolism, and cellular signaling
linked with immune response (Fig. 2A).
Among the statistically significantly affected (B-H P < 0.05) canonical
pathways, ten with highest B-H P values are presented in the Fig. 2B.
Majority of the affected pathways were shared between all four
conditions, but for E2-HRT vs. non-HRT, the associations were in most
cases statistically nonsignificant. This may indicate that the use of E2-HRT
suppresses some of the aging effects. This finding is in line with our
earlier transcriptomic study (Po¨lla¨nen et al., 2007), which demonstrated
that the use of E2-HRT mitigates genome-wide changes in post-
menopausal women’s muscle gene expression. Significant age associa-
tions were found for 18 pathways without E2-supplementation and for
Table 3 The intrapair differences of postmenopausal twins. Statistically significant P-values are marked in bold
E2-based HRT (n = 6 pairs) Tibolone-based HRT (n = 3 pairs)
Group comparison
IPD P-value IPD P-value P-value
Body composition
BMI 2.78  3.88 0.140 1.07  1.59 0.363 0.152
Waist circumference 7.20  10.32 0.148 0.67  3.55.0 0.774 0.253
Hip circumference 3.78  4.83 0.114 0.89  0.92 0.236 0.354
Body fat mass 6.82  6.76 0.057 1.44  3.97 0.594 0.097
LBM 0.06  3.79 0.972 2.45  2.76 0.265 0.349
Muscle performance
Handgrip 25.53  69.32 0.408 39.30  77.66 0.473 0.794
Power 3.58  2.89 0.029 1.41  1.20 0.179 0.262
Specific force 0.48  0.94 0.268 2.11  0.53 0.020 0.003
Systemic hormones†
E2 187.17  275.10 0.027 0.67  5.13 0.785 0.024
Testosterone 40.0  95.71 0.462 423.33  268.39 0.109 0.024
DHT 0.03  0.08 0.345 0.13  0.17 0.276 0.381
DHEAS 0.22  2.01 0.917 1.44  1.25 0.109 0.262
SHBG 25.08  25.45 0.028 49.40  24.57 0.109 0.024
LH 7.92  10.09 0.116 3.73  9.88 0.593 0.262
FSH 30.98  33.79 0.075 22.2  7.28 0.109 1.0
Intramuscular hormones†
E2 0.11  0.28 0.399 0.22  0.13 0.109 0.167
Testosterone 1.18  2.28 0.345 1.59  0.82 0.109 0.381
DHT 0.12  0.17 0.046 0.19  0.13 0.109 0.381
DHEA 5.78  17.48 0.600 14.63  7.38 0.109 0.262
IPD = intrapair difference, E2 = 17b-estradiol, HRT = hormone replacement therapy, BMI = body mass index, LBM = lean body mass, DHT = dihydrotestosterone, DHEA(S)
= dehydroepiandrosterone (sulfate), LH = luteinizing hormone, FSH = follicle-stimulating hormone, SHBG = serum hormone-binding globulin.
†Due to nonlinear distribution of hormone variables, Wilcoxon signed rank test for related samples was used to test significance of intrapair difference (IPD = HRT user value
– nonuser value) within twin pairs and Mann–Whitney U-test for independent samples was used to test significance of IPD between groups.
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18 pathways with E2-supplementation in contrast to 19 pathways
identified in E2-HRT vs. non-HRTs comparison, and seven pathways in
Tib-HRT vs. non-HRT comparison (Fig. 2B, Table S4, Supporting
information). The potential protective role of HRT was not always
associated with the use of Tib-HRT. For example, glycolysis, mitochon-
drial dysfunction, aspartate degradation, and tricarboxylic acid (TCA)
cycle pathways were significantly enriched in the Tib-HRT vs. non-HRT in
comparison with E2-HRT vs. non-HRT (Fig. 2B).
Upstream regulators and downstream functions associated
with female muscle
In order to identify potential upstream effectors behind the observed
protein level differences and to further anticipate which downstream
functions are affected, we subsequently performed up- and downstream
analyses with IPA. These analyses were based on the Ingenuity
Knowledge Base regarding the associations between the multitude of
upstream effectors and their targets which is combined with the
measured observations, that is, our lists of DEPs.
Such analyses pinpointed E2 (17b-estradiol) as one of the putative
upstream effectors (Fig. 3A). Based on the observed alteration in muscle
protein abundancies, IPA predicted E2 levels to be downregulated in all
four comparisons except in Tib-HRT vs. non-HRT cotwins. To validate this
prediction, E2 concentration was measured from muscle and serum
samples in an independent set of experiments. The measured E2
concentration was not statistically different between groups in the
muscle (Table 1 and Fig. 3B); however, the concentration of circulating,
systemic E2 in the serum followed the IPA predictions in three of four
conditions (Table 2 and Fig. 3C). The IPA prediction failed to reflect the
order of E2 difference only in the E2-HRT vs. non-HRT comparison, in
which the measured E2 level was higher in the E2-HRT users as compared
to the nonusers although IPA algorithm predicted it to be downregu-
lated. E2-HRT and non-HRT women are MZ cotwins, which makes them
very similar to each other. IPA cannot consider the cotwin design in the
analysis; thus, the low genetic variance between groups may violate the
correct prediction in the IPA’s upstream analysis. However, several E2-
associated DEPs were identified for each group comparison (Fig. 4A–D).
The predicted downstream functions pointed to cell death and
glycolytic pathways (Fig. 3D), which complements the canonical path-
ways analyses identifying glycolysis/gluconeogenesis as well as oxidative
phosphorylation/mitochondrial dysfunctions among others to be
affected by aging and use of HRT (Fig. 2). To get further insight and
to verify that E2 is one of the key players for the predicted change in
downstream cellular functions, we compared the proteins known to be
associated with E2 (Fig. 4A–D) with proteins contributing to the cell
death and glycolysis pathways (Fig. 3E), and identified 22 shared
proteins with E2 and cell death pathways, two associated with E2 and
glycolysis and two shared between all three lists. These results are
supported by the measured muscle phenotype observations (Tables 2
and 3), which show uppermost muscle performance with highest levels
of circulating E2, that is, in the premenopausal women and lowest
muscle performance among non-HRT women who concomitantly had
the lowest circulating E2 level. Furthermore, these results indicate that
aging-associated decrements in muscle function may be mediated by cell
death and glycolytic pathway-associated DEPs and to be partially
E2-regulated.
Functional validation of differentially expressed protein
targets associated with estradiol
To complement and functionally validate the bioinformatics analyses,
which identified E2 as significant upstream regulator of the muscle
functions, we performed in vitro experiment with human muscle primary
Fig. 1 Characterization of female muscle proteome. (A) Venn diagram
comparison of differentially expressed proteins (DEPs) in relation to the differences
in age with or without hormone replacement therapy (HRT) treatments. (B) Venn
diagram comparison of DEPs in relation to differences in the HRT specimen (E2-
based or tibolone-based). (C) Comparison of quantitative proteomics data with
literature findings. Twenty-eight proteins were identified in previous proteomic
studies by Theron et al. and Gueaugneau et al., while 93 of the proteins were
novel. PRE = premenopausal group, non-HRT = postmenopausal women not
using HRT, E2-HRT = postmenopausal women using 17b-estradiol-based HRT,
Tib-HRT = postmenopausal women using tibolone-based.
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cells. Muscle progenitor cells were induced to differentiate from single
nucleated myoblasts to multinucleated myotubes, which were then
exposed to the E2. To follow the observed differences in the MS
E
analyses on the cellular level, we confirmed the expression of selected
E2-associated DEPs by semi-quantitative Western blotting from the
myotubes exposed to mock conditions, and to 10 nM E2 or 100 nM E2 for
6 h.
We selected two DEPs predicted to be upregulated with lower E2
(non-HRT vs. PRE and E2-HRT vs. PRE) for validation. These proteins were
aldolase fructose-bisphosphate A (ALDOA) and cullin 4A (CUL4A), with
important functions in energy pathways and in the regulation of cell
cycle. ALDOA is a glycolytic enzyme that catalyzes the reversible
conversion of fructose-1.6-bisphosphate to glyceraldehyde 3-phosphate
and dihydroxyacetone phosphate (Hittel et al., 2005), while CUL4A is E3
ubiquitin ligase with oncogenic effects through modulation of cell
growth and immune response (Saucedo-Cuevas et al., 2014). Further-
more, three DEPs predicted to be downregulated with lower E2 were
also selected for semi-quantitative analysis. These included lactate
dehydrogenase A (LDHA), mitochondrial cytochrome c oxidase II (MT-
CO2), and muscle pyruvate kinase (PKM), which all have connections to
muscle energy metabolism. Muscle LDHA catalyzes the conversion of
lactate to pyruvate in the final step of anaerobic glycolysis (Kolappan
et al., 2015). MT-CO2 is the component of mitochondrial respiratory
chain. Mutations in MT-CO2 lead to MELAS, a multisystem disorder
characterized by mitochondrial myopathy, lactic acidosis, and stroke-like
episodes followed by seizures, recurrent headaches, and muscle weak-
ness (Rossmanith et al., 2009). The expression of PKM, which catalyzes
the rate-limiting final step in glycolysis, has been shown to be induced by
Fig. 2 Functional analysis of the muscle proteome. (A) Functional distribution of differentially expressed proteins (DEPs) contributing to the canonical pathways (B) revealed
substantial overlap and pinpointed the major differences in the expression to affect mitochondria (e.g., oxidative phosphorylation), cytoplasmic energy metabolism and
various cellular signaling modules. (B) Canonical pathways analysis. Ten pathways with most significant Benjamini–Hochberg corrected P-values are presented.
PRE = premenopausal group, non-HRT = postmenopausal women not using HRT, HRT = hormone replacement therapy, E2-HRT = postmenopausal women using
17b-estradiol-based HRT, Tib-HRT = postmenopausal women using tibolone-based, B-H = Benjamini–Hochberg correction.
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E2 having critical role in metabolic reprogramming of proliferating cells
toward aerobic glycolysis (Salama et al., 2014). Taken together, ALDOA,
PKM, and LDHA have shared functions in glycolysis and cell death
pathways while CUL4A and MT-CO2 play a role in cell death.
The immunoblotting with ALDOA and CUL4A antibodies demon-
strated a statistically significant change in protein expression upon
treatment with 100 nM E2 (mock vs. E2; FC = 1.3, P = 0.01 for ALDOA
and FC = 1.9, P = 0.007 for CUL4A), corroborating the results of HD-
MSE (Fig. 5). Similarly, to the result of proteomic survey, immunoblotting
with PKM antibody, which was predicted to be downregulated by IPA,
demonstrated a trend for downregulation (mock vs. low E2; FC = 1.3);
however, the difference between treatments was not statistically
significant. Upon 10 nM E2 treatment, LDHA expression increased by
1.2-fold (P = 0.033), while MT-CO2 by 1.5-fold, which however was not
statistically significant. The observed discrepancy for LDHA and MT-CO2
with corresponding proteomics measurements indicates that either
Fig. 3 Upstream and downstream functions associated with female muscle aging with or without hormone replacement. (A) The upstream regulator analysis predicted
17b-estradiol (E2) as one of the key upstream regulators behind the observed differences in muscle protein expression. (B) Fold change (FC) values of E2 measured from the
muscle biopsy samples. The numbers at the end of the bars are P-values. (C) Fold change (FC) values of the systemic E2 measured from the serum samples of pre- and
postmenopausal women. The numbers at the end of the bars correspond to P-values. (D) The downstream effect analysis predicted cell death, glycolysis, and muscle function
pathways to be affected based on the observed differences in muscle protein expression. ROS = reactive oxygen species. (E) Comparative analysis of E2-, cell death- and
glycolysis-associated differentially expressed proteins. IPA predicts cell death and glycolysis to be among the most affected downstream processes while E2 was predicted as
an upstream regulator. However, the contributing DEPs for this prediction do not completely overlap. PRE = premenopausal women, non-HRT = postmenopausal women
not using HRT, HRT = hormone replacement therapy, E2-HRT = postmenopausal women using 17b-estradiol-based HRT, Tib-HRT = postmenopausal women using tibolone-
based HRT. The number of contributing DEPs is indicated.
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Fig. 4 Comparative analysis of 17b-estradiol (E2) regulated differentially expressed proteins (DEPs). (A) The DEPs identified in postmenopausal women without hormone
replacement (HRT) in comparison with premenopausal women (non-HRT vs. PRE). (B) Comparison of E2-regulated DEPs among postmenopausal E2-HRT users and
premenopausal women (E2-HRT vs. PRE). (C) Comparison of the E2-regulated DEPs in postmenopausal E2-HRT users and their nonusing cotwins (E2-HRT vs. non-HRT). (D) E2-
regulated DEPs in the postmenopausal Tib-HRT users in comparison with their nonusing cotwins (Tib-HRT vs. non-HRT). The DEPs associated with the predicted downstream
functions related to cell death and glycolysis as well as associated with mitochondrial functions are presented. Blue stars indicate DEPs with expression change validated by
semi-quantitative immunoblotting. ML = my lists are assembled by including all the observed DEPs involved in the corresponding pathways in any of the four conditions. ML:
cell death and ML: glycolysis, originate from the analysis presented in the Fig. 3D, while ML: mitochondrial functions from the canonical pathways oxidative phosphorylation
and mitochondrial dysfunction presented in the Fig. 2B. Arrows indicate the predicted inhibition or activation of the entire cascade.
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longer E2 exposure time might be required to downregulate LDHA and
MT-CO2 expression in the muscle primary cells or other, yet unidentified
factors, which are not represented in vitro, play a role in this process in
the skeletal muscle tissue.
Concluding remarks
Female aging is characterized by menopausal change in sex steroid
hormones concomitant to increase in aging-related decrements in
skeletal muscle performance that can be attenuated by HRT use (Sipila¨
et al., 2015). The molecular mechanisms underpinning menopausal
decrements in muscle function are poorly known. Our label-free
proteomic analyses have resulted in the quantification of 797 muscle
proteins. Among those identified, 27 have been formerly investigated in
large-scale female muscle proteome studies (Gueugneau et al., 2014;
Theron et al., 2014), while 145 were now described for the first time to
our knowledge. Among the identified novel DEPs, 79 were measured in
both aging conditions, with or without HRT, indicating them to be age-
responsive and insensitive to the use of HRT. In addition, 17 novel
proteins were differentially expressed in postmenopausal women with-
out HRT and 49 with HRT in comparison with the premenopausal
women.
The major canonical pathways found to be differentially regulated
included mitochondrial dysfunction, oxidative phosphorylation, glycoly-
sis, and TCA-cycle, strong indicators for affected energy metabolism. The
major biological processes predicted to be affected were related to cell
death, apoptosis, and cell survival, as well as contractility of the muscle
and glycolysis. Furthermore, E2 was predicted to be an upstream
regulator of these processes, which we confirmed by exposing myotubes
to E2 in vitro. Previous experimental animal studies have implicated E2 in
mitochondrial functions and metabolic homeostasis in skeletal (Capl-
lonch-Amer et al., 2014; Cavalcanti-de-Albuquerque et al., 2014; Ribas
et al., 2016), and cardiac muscle (Rattanasopa et al., 2015; Sbert-Roig
et al., 2016). In addition, previous studies have shown E2 to exert anti-
apoptotic effects in muscle progenitor cells by improving mitochondrial
function (La Colla et al., 2013).
Being in line with previous experimental studies, our study suggests,
for the first time at human proteome level, that E2 is a major regulator of
human skeletal muscle signaling in women. After menopause, when
ovarian E2 production is ceased, the prevalence of cardio-metabolic
diseases increases. Our result that different trajectories of the energy
pathways in the skeletal muscle may be regulated by E2 provides
candidate molecules as key targets for future interventions to prevent or
treat postmenopausal metabolic dysregulation. Further studies should
focus on validation of the pathways identified in this study, to
corroborate E2 as their direct upstream regulator.
Experimental procedures
Subjects and study design
The participants represented part of the SAWEs study, for which the
details of recruitment and data collection have been reported earlier
(Ronkainen et al., 2009; Po¨lla¨nen et al., 2011). The current study utilizes
data and skeletal muscle (m. vastus lateralis) samples of six healthy
premenopausal women and 18 healthy women from nine pairs of
postmenopausal monozygotic cotwin sisters. Premenopausal women
were recruited by postal enquiry sent to two thousand women randomly
selected from the entire 30- to 40-year-old age cohort (born in 1967–
1977) living in the City of Jyva¨skyla¨, Finland. Among the respondents, 59
were eligible after consideration of exclusion criteria (i.e., ongoing or
previous (past 5 years) use of hormonal contraceptives, pregnancy, or
breastfeeding). Six (10%) were selected at random for the current
proteomic study (PASW Statistical Software, SPSS Inc., IBM, IL, USA).
Postmenopausal women were recruited from the Finnish Twin Cohort
(Kaprio & Koskenvuo, 2002). Postmenopausal twin pairs aged 54–
62 years were asked to participate in SAWEs study if the other cosister
had never used HRT and the other was a current HRT user. Total of 15
monozygotic twin pairs met the inclusion criteria and were willing to
participate as described earlier (Ronkainen et al., 2009). Twin pairs were
discordant for the HRT including nine non-HRT users and their nine
cotwins currently using HRT. This study was approved by the Local
Ethical Committee of the Central Finland Hospital District (E0606/06)
Fig. 5 Validation of the proteomic results by semi-quantitative Western blotting in
primary human muscle cells. Representative images of the Western blots from cell
culture experiments with human muscle primary cells. Quantification of the
immunoblots was performed with three independent cell experiments exposed to
the statistical testing using independent samples t-test. Data are presented as
mean  standard deviation. M = mock, 10 = 10 nM E2, 100 = 100 nM E2.
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and performed following guidelines of the Helsinki Declaration and good
clinical and scientific practice. All study participants provided written
informed consent.
Study participants went through a medical examination during which
a physician confirmed their general health status, gynecological history,
absence of possible chronic or acute illnesses, and use of medication.
Data on current and past smoking, alcohol consumption, and physical
activity habits were collected with a standard questionnaire. Anthropo-
metric and body composition measurements were performed between
07:00 and 10:00 after overnight fasting and were after standardized
breakfast followed by muscle strength and power measurements. Body
weight was measured with beam scale and height with a stadiometer
and body mass index (BMI) calculated (weight, [kg]/height [m2]). Waist
circumference was measured midway between spina iliaca superior and
the lower rib margin and hip circumference at the level of the greater
trochanters. Body fat mass and lean body mass (LBM) were measured
with a multifrequency bioelectrical impedance analyzer (InBody 720;
Biospace, Seoul, Korea). Maximal handgrip force was measured with an
adjustable dynamometer chair (Good Strength, Metitur, Palokka,
Finland). The explosive lower body muscle power, that is, ability to
produce force as quickly as possible, was assessed with counter
movement jump on a contact mat. Maximal isometric knee extension
force was measured in a sitting position using an adjustable dynamome-
ter chair (Good Strength, Metitur, Palokka, Finland). In all measure-
ments, three to five trials were allowed and the maximal performance
was accepted as the result. Quadriceps muscle cross-sectional area was
assessed from the computed tomography scans (Siemens Somatom
Emotion Scanner; Siemens, Erlangen, Germany) and used to calculate
specific force as maximal isometric knee extension force divided by
muscle cross-sectional area (Po¨lla¨nen et al., 2011).
Blood and skeletal muscle samples and hormone assessments
Blood samples were taken between 08:00 and 10:00 h in standardized
fasting conditions at supine position. For premenopausal women,
samples were collected during 1-5 days of estrous cycle. Muscle biopsies
were taken following blood sampling from the mid-part of the m. vastus
lateralis. Visible blood, fat, and connective tissue were removed before
the biopsy sample was mounted on the cork with Tissue Tek Optimal
Cutting Temperature compound (OCT, Sakura; Alphen aan dae Rijn, the
Netherlands), frozen rapidly in 2-methylbutane (Sigma-Aldrich Corpora-
tion, St. Louis, MO, USA) precooled to 160 °C in liquid nitrogen, and
stored at 80 °C until used for protein analysis. Serum and muscle
hormone assessments were carried out as in (Po¨lla¨nen et al., 2011).
Briefly, serum concentrations of sex hormone-binding globulin (SHBG),
dihydroepiandrosterone sulfate (DHEAS), follicle-stimulating hormone
(FSH), and luteinizing hormone (LH) were measured using solid-phase,
chemiluminescent immunometric assays (Immulite 1000, Diagnostic
Products, Los Angeles, CA, USA). Serum 17b-estradiol (E2) was deter-
mined using an extraction radioimmunoassay, while testosterone and
dihydrotestosterone (DHT) were measured separately using LC-MS/MS.
Muscle samples were homogenized on ice in Tissue Extraction Reagent I
(Invitrogen, Carlsbad, CA, USA) supplemented with protease and
phosphatase inhibitors. The amount of total soluble protein was
determined using Pierce BCA Protein Assay-kit (Thermo Scientific,
Rockford, IL, USA). Muscular E2, testosterone, DHT, and DHEA concen-
trations were determine using ELISA tests (IBL-international, Hamburg,
Germany) from 1:10 diluted muscle supernatants in duplicates. The
concentrations of muscular hormones were expressed as nmol 9 g1
soluble muscle protein.
Sample preparation and proteolytic digestion of proteins
from muscle samples
Frozen muscle samples were thawed on ice, detached from cutting
block, and submersed in milliQ water to wash excess amounts of OCT.
Subsequently, they were dipped in 4% SDS/0.1 M Tris pH 8/0.05 M DTT
and homogenized at room temperature using tissue homogenizer. The
homogenate was heated for 10 min at near 100 °C and cleared by
centrifugation at 30 000 g for 15 min. The protein concentration was
determined using the nanodrop technique. 10 lg of total protein was
digested, using modified FASP protocol (Scifo et al., 2015). In brief, the
lysate buffer was exchanged by washing it several times with 8 M urea,
0.1 M Tris, pH 8 (urea buffer, UB). The proteins were alkylated with
50 mM iodoacetamide in UB, after washing out the DTT-containing
solution. 1:50 w/w of lysine-C endopeptidase (Wako) was added in
about 4 M urea/0.1 M Tris pH 8 and incubated at room temperature
overnight. The peptide digests were collected by centrifugation, and
trypsin solution was added in a ratio of 1:50 w/w in 50 mM ammonium
bicarbonate. As before, the digests were collected and combined. The
peptide samples were cleaned using C18—reverse phase ZipTipTM
(Millipore), resuspended in 1% TFA and sonicated in water bath for 1 min.
Liquid chromatography high-definition tandem mass
spectrometry
The samples were analyzed in randomized order. 300 ng of digested
proteins/replicate (three technical replicates per sample) was used in
nano-LC-HD-MSE analysis. The nano-LC-HD-MSE analyses were per-
formed as described (Ma¨kela¨ et al., 2016; Tikka et al., 2016). Briefly, the
peptides were separated by nanoAcquity UPLC system (Waters)
equipped with a trapping column (5 lm Symmetry C18
180 lm 9 20 mm C18 reverse phase, Waters), and followed by an
analytical C18 BEH130 reversed-phase column (75 lm 9 250 mm,
particle size 1.7 lM; Waters) in a single pump trapping mode. After
trapping, the peptides were separated with a linear gradient of 3–35%
of solution B (0.1% formic acid/acetonitrile), for 90 min at a flow rate
0.3 lL min1 and stable column temperature of 35 °C. Each sample run
was followed by two empty runs to wash out any remaining peptides
from previous runs. The samples were run in ion mobility-assisted data-
independent analysis mode (HD-MSE), in a Synapt G2-S mass spectrom-
eter (Waters), by alternating between low collision energy (6V) and high
collision energy ramp in the transfer compartment (20–45 V) and using
1 s cycle time. The separated peptides were detected online with mass
spectrometer, operated in positive, resolution mode in the range of m/z
50–2000 amu. 150 fmol lL1 of human [Glu1]-fibrinopeptide B (Sigma)
in 50% acetonitrile/0.1% formic acid solution at a flow rate of
0.3 lL min1 was used for a lock mass correction, applied every 30 s.
Database mining of proteomics data
Relative quantification between samples using precursor ion intensities
was performed with Progenesis QITM Informatics for Proteomics software
(Nonlinear Dynamics/Waters) and ProteinLynx Global Server (PLGS V3.0).
HD-MSE parameters were set as follows: low energy threshold of 135
counts, elevated energy threshold of 30 counts, and intensity threshold
of precursor/fragment ion cluster 750 counts. Chromatograms were
automatically aligned by the Progenesis QITM software, and those with
alignment score ≥70% to the reference run were selected for further
analysis. All spectra were manually checked following alignment, and
additional vectors were added to improve the scoring. The percentage of
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rejected runs was <5%. To compare the controls to other subjects, we
utilized the between-subject design scheme of Progenesis QITM software.
Database searches were carried out against UniProt-SwissProt
reviewed human database (release 2017_6, 48614 entries) with Ion
Accounting algorithm as described (Ma¨kela¨ et al., 2016; Tikka et al.,
2016). Following parameters were used: peptide and fragment toler-
ance: automatic, maximum protein mass: 500 kDa, min fragment ions
matches per protein ≥7, min fragment ions matches per peptide ≥3, min
peptide matches per protein ≥1, primary digest reagent: trypsin, missed
cleavages allowed: 2, fixed modification: carbamidomethylation C,
variable modifications: deamination of N/Q residues, oxidation of
Methionine (M), and false discovery rate (FDR) <4%. Protein quantitation
was performed entirely on nonconflicting Homo sapiens identifications,
using precursor ion intensity data and standardized expression profiles.
Protein was considered to be identified when it was present in all three
replicates of the nano-LC-HD-MSE runs and within a study group when
identification failed in less than in 33% of the participants (i.e., protein
called present at least four of six participants within premenopausal
group and at least seven of nine participants within postmenopausal
group).
Functional analysis of proteomics data
DEPs (P < 0.05 by ANOVA for all comparisons), which were quantified
based on ≥2 unique peptides, served as inputs into IPA (Ingenuity
Systems, Redwood City, CA; www.ingenuity.com). Prior to network and
other functional analyses, the list of proteins was filtered to include only
proteins with fold changes, FC greater than |1.5|. The IPA right-tailed
Fisher’s exact test with B-H multiple testing corrections was used to
determine a P-value of significance in all functional analyses.
Functional validation of proteomics data
Primary human muscle cell line that was derived from the quadriceps
muscle biopsy of a 5-day-old female infant (Edom et al., 1994) was
kindly provided by Profs Moyly and Buttler-Browne (INSERM, Paris,
France). Proliferating mononuclear myoblasts were differentiated for
5 days to form multinuclear myotubes in E2 free environment, before
exposing them to 10 nM E2, 100 nM E2 or mock for 6 h. All experiments
were carried out in triplicate. Semi-quantitative immunoblotting analysis
was carried out to quantitate the protein expression of CUL4A, MT-CO2,
LDHA, ALDOA, and PKM. TUBA was used for normalization. The blots
were scanned and quantified using Odyssey CLX Infrared Imager of Li-
COR and manufacturer’s software. Cell culture mediums, fetal bovine
serum, and antibiotics were obtained from Life Technologies, Inc.
(Carlsbad, CA, USA) while insulin from Sigma-Aldrich. CUL4A, MT-CO2,
and LDHA antibodies were purchased from Cell Signaling Technology
(Danvers, MA, USA), ALDOA and PKM from Abcam (Cambridge, UK)
and TUBA from Sigma-Aldrich. As a secondary antibodies, anti-rabbit IR
Dye 800 or anti-mouse IR Dye 680 (LI-COR Biosciences, Lincoln, NE, USA)
was used.
Statistics
Statistical testing regarding phenotype variables and cell experiment was
carried out with SPSS version 24 (IBM, Chicago, IL, USA). Shapiro–Wilk
test and visual inspection of the normality plots were used to inspect
normal distribution of the variables. Based on distribution, either
independent samples t-test or Mann–Whitney U-test (in case of
unrelated groups) or paired-samples t-test or Wilcoxon signed rank test
(in case of twin pairs) were used.
Accession numbers
The proteome data reported in this study are available in the Proteomics
IDEntifications (PRIDE) data repository under accession number
PXD006446 (Vizcaıno et al., 2016).
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